

Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial

Submission date 24/04/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 09/06/2008	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 12/04/2021	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Willem Lems

Contact details
Vrije University Medical Centre
De Boelelaan 1117
Amsterdam
Netherlands
1081 HV
-
wf.lems@vumc.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
CW-004-IN

Study information

Scientific Title

Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial

Study objectives

The aim of this trial was to assess the preference for a formulation based on the identification of some of the factors that may influence compliance with the intake of calcium plus vitamin D3 supplements.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Local Ethical Committee in February 2003.

Study design

Randomised, open, cross-over clinical trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Osteoporosis

Interventions

The Calci-Chew D3 chewable tablets (Nycomed, Denmark) contained 1250 mg of calcium carbonate (equivalent to 500 mg elemental calcium) and 400 IU of cholecalciferol (equivalent to 10 µg vitamin D3). The sachet of calcium plus vitamin D3 (Cad, Will-Pharma) contained 1250 mg of calcium carbonate (equivalent to 500 mg elemental calcium) and 440 IU of vitamin D3.

The patients received both trial medications for 14 days, which was considered adequate for a patient to become familiar with the formulation and to assess the preference and acceptability. The patients received either the chewable tablet for two weeks followed by the sachet for two weeks or vice versa.

Total duration follow-up: 28 weeks

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Calcium, vitamin D3 supplementation

Primary outcome measure

To assess any preference between Calci-Chew D3 and Cad, measured at visit 3 (day 28).

Secondary outcome measures

1. To compare acceptability of the formulations using an 11-point rating scale, measured at visit 2 (day 14) and visit 3 (day 28)
2. To record tolerability and adverse events, measured at visit 2 (day 14) and visit 3 (day 28)

Overall study start date

01/02/2003

Completion date

30/11/2003

Eligibility**Key inclusion criteria**

1. Patients with osteoporosis who required calcium and vitamin D supplementation as part of their anti-osteoporotic therapy
2. Age range: greater than 18 years, gender: women and men

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

200

Total final enrolment

102

Key exclusion criteria

1. Use of the trial medications during the past six months
2. Any condition for which the trial medications are contra-indicated, such as hypercalcaemia, hypercalciuria, Zollinger-Ellison syndrome, and nephrolithiasis
3. Use of drugs known to interact with the trial medications (e.g., digoxin, tetracycline, fluoroquinolones, bisphosphonates, iron, sodium fluoride, diuretics, phenytoin, barbiturates, corticosteroids, levothyroxine, ion exchange resins, laxatives)
4. Planned surgery during the four-week study period
5. Pregnant, possibly pregnant, or breastfeeding women

Date of first enrolment

01/02/2003

Date of final enrolment

30/11/2003

Locations

Countries of recruitment

Netherlands

Study participating centre

Vrije University Medical Centre

Amsterdam

Netherlands

1081 HV

Sponsor information

Organisation

Nycomed (Denmark)

Sponsor details

Langebjerg 1

Roskilde

Denmark

DK-4000

-

Info@nycomed.com

Sponsor type

Industry

Website

<http://www.nycomed.com/en/menu/>

ROR

<https://ror.org/03bsswy66>

Funder(s)

Funder type

Industry

Funder Name

Nycomed (Denmark)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/05/2010	30/12/2020	Yes	No